There have been many potential targets identified for the treatment of advanced prostate cancer. Many of these targets are being actively explored with clinical trials designed to test some inhibitors of the targets. Antisense oligonucleotides (OGX-011) targets clusterin, a chaperone protein and OGX-427 which targets heat-shock protein 27 are among the inhibitors being evaluated. OGX-011 [...]
Osteoblasts and osteoclasts are the process that the body uses to breakdown old bone and then to rebuild it with new bone. c-Met is a tyrosine kinase expressed by osteoblasts and osteoclasts, and overexpressed by prostate cancer cells. This over expression leads to the eventual development of bone metastases. The experimental treatment known as Cabozantinib [...]
Are you the kind of guy that uses his laptop computer in your lap? Many of us do this when we are in our car or even seated on our couch while we watch TV. If we don’t most of our children and granchildren do. According to research presented at the American Society for Reproductive [...]
Since it FDA approval in 2004, docetaxel (a taxane based chemotherapy) has been the standard first-line chemotherapy for men with metastatic prostate cancer (mCRPC). Other than the trial of Provenge all the successful phase III trials conducted in mCRPC focused on men experiencing cancer progression after first-line docetaxel chemotherapy. The implication is that improving the [...]
Approximately one third of all men diagnosed and treated for prostate cancer will experience a recurrence of their prostate cancer! This is a shocking number, but it is a true number. It does not matter what the treatment a man has, the statistic holds up across all treatments. The first sign of a problem, a [...]